Hybritech, Inc. Work Values

Daily Duties at Hybritech, Inc.:

In vitro monoclonal antibody (MAb) based ELISA assays, including products for PSA, CEA, HCG, AFP, CKmb and IgE were developed. Ex-vivo applications of MAbs to lymphoma and graft-versus-host disease were developed for clinical investigations. Developed treatments for therapeutic treatment of B cell and T cell lymphomas. Developed products for In vivo diagnostic imaging of solid tumors including melanoma, colon, breast, lung and prostate cancers. The first USFDA approved MAb for in vivo diagnosis of occult colon cancer was discovered and developed. An R&D partnership for $73 M was formed. The first human MAb for breast cancer was developed. Radiation, drug and toxin linked antibodies were developed. Second generation bispecific IgG antibodies were developed with clinical proof-of-principle and patented. The first enzyme antibody conjugates were developed for use in site specific prodrug delivery to target tumor tissues. The technology that was the basis of IDEC pharmaceuticals (now Biogen-IDEC Pharmaceuticals). Responsibility centers for pilot operations, operations, quality control, quality assurance, regulatory affairs, clinical trials, data management, biostatistics and data analysis were initiated and subsequently relinquished to individuals hired to specifically manage each responsibility center. Assisted in the complete corporate acquisition by Eli Lilly Company & promoted to Vice President Therapeutics R&D. The only individual out of 1385 corporate members selected to report to Eli Lilly Company as a member of senior management (Executive Director). Formally trained by Eli Lilly in personnel and project management. Member of the Eli Lilly drug class evaluation team. Member of the Hybritech Senior Management Team with membership responsibility for personnel evaluations, compensation committee and to a lesser extent diagnostic product strategy. Participated in senior management personnel motivation meetings. Extensively published with numerous speaking engagements and awards, including the key note address for the 4th International Monoclonal Antibody Conference.

What they like about Hybritech, Inc.:

Working in an organization that is technologically advanced, creative, and innovative is critical in your assessment of hiring companies. Less important to you are stability of the organization, the length of time an organization has been in business, and the business' plans for the future. You prefer a fast-moving company that will take risks to achieve its goals and objectives. The length of time the company has been in business is irrelevant. Maintaining status quo is unnecessary. You thrive on change, uncertainty and the upside of potential business risks, especially those associated with innovation. Stability for the long haul is not nearly as important as is working in an atmosphere that is charged with a sense of urgency and constant change.

Tags

Biotechnology • International Business • Expense Control • Joint Ventures • Technical Writing • Regulatory Reporting Corporate Development • New Drugs • Biologics • Cell Therapy • Cross-Functional Science Management • Chemistry Budgeti, Molecuar Biology, Receptor Identification

Skills

Biotechnology, International Business, Expense Control , Joint Ventures , Technical Writing , Regulatory Reporting, Corporate Development , New Drugs , Biologics, Cell Therapy , Cross-Functional Science Management , Chemistry, Budgeting , Change Management , Recruiting , Strategic Planning , New Drug Development , Public Relations, Start Ups / Turnarounds , Negotiations , Presentations , Intellectual Property , IPOs, OSHA / Regulatory Compliance , Project Management, Business Development, Clinical Trials , Biologics , QA/QC, Regenerative Medicine , Drug Pharmacokinetics , Drug Metabolism / Disposition , Corporate Governance , Patents, Workforce Planning , Complex Problem Solving , Intellectual Property, Product Development , Process Development / Production , Regulatory Compliance , Investor Relations , Retention, Cost Center Accountability , Shareholder Annual Reports , Board / Shareholder Meetings , Capital Formation , SEC Filings , Needs Assessment , Risk Management , Corporate Safety

These are some of the questions we asked our climbers about their experiences with Hybritech, Inc.: